全文获取类型
收费全文 | 270639篇 |
免费 | 16134篇 |
国内免费 | 7559篇 |
专业分类
耳鼻咽喉 | 3508篇 |
儿科学 | 8676篇 |
妇产科学 | 3144篇 |
基础医学 | 19154篇 |
口腔科学 | 6830篇 |
临床医学 | 32022篇 |
内科学 | 44970篇 |
皮肤病学 | 3304篇 |
神经病学 | 13635篇 |
特种医学 | 26190篇 |
外国民族医学 | 42篇 |
外科学 | 37640篇 |
综合类 | 26610篇 |
现状与发展 | 29篇 |
预防医学 | 16487篇 |
眼科学 | 7493篇 |
药学 | 25787篇 |
92篇 | |
中国医学 | 4878篇 |
肿瘤学 | 13841篇 |
出版年
2023年 | 2767篇 |
2022年 | 4919篇 |
2021年 | 11066篇 |
2020年 | 6958篇 |
2019年 | 12697篇 |
2018年 | 7413篇 |
2017年 | 6557篇 |
2016年 | 8459篇 |
2015年 | 11455篇 |
2014年 | 20877篇 |
2013年 | 18111篇 |
2012年 | 21535篇 |
2011年 | 18858篇 |
2010年 | 17074篇 |
2009年 | 16671篇 |
2008年 | 15552篇 |
2007年 | 15497篇 |
2006年 | 13407篇 |
2005年 | 9425篇 |
2004年 | 5618篇 |
2003年 | 4569篇 |
2002年 | 3665篇 |
2001年 | 3018篇 |
2000年 | 2716篇 |
1999年 | 1861篇 |
1998年 | 2158篇 |
1997年 | 2016篇 |
1996年 | 1735篇 |
1995年 | 1777篇 |
1994年 | 1693篇 |
1993年 | 1330篇 |
1992年 | 1440篇 |
1991年 | 1295篇 |
1990年 | 1294篇 |
1989年 | 1233篇 |
1988年 | 1170篇 |
1987年 | 1026篇 |
1986年 | 830篇 |
1985年 | 1770篇 |
1984年 | 1936篇 |
1983年 | 1376篇 |
1982年 | 1497篇 |
1981年 | 1455篇 |
1980年 | 1236篇 |
1979年 | 1060篇 |
1978年 | 808篇 |
1977年 | 815篇 |
1976年 | 692篇 |
1974年 | 468篇 |
1973年 | 444篇 |
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
92.
93.
94.
95.
《Cirugía espa?ola》2022,100(11):709-717
ObjectiveMost evidence, including recent randomized controlled trials, analysing anal squamous cell carcinoma (SCC) do not consider immunocompromise patient population. The aim of this study was to compare clinical and oncological outcomes among immunocompetent and immunocompromised patients with anal squamous cell carcinoma.MethodMulticentric retrospective comparative study including 2 cohorts of consecutive patients, immunocompetent and immunocompromised, diagnosed with anal SCC. This study evaluated clinical characteristics, clinical response to radical chemoradiotherapy (CRT) and long-term oncological results including both local and distant recurrence, overall survival (OS) and disease-free survival (DFS).ResultsA total of 84 patients, 47 (55.6%) female, diagnosed with anal SCC from January 2012 to December 2017 were included, 22 (26%) and 62 (74%) patients in immunocompromised and immunocompetent groups respectively. Patients in immunocompromised group were significantly younger (53 vs. 61 years; P=0.001), with smaller tumoral size (P=0.044) and reported higher rates of substance abuse.including tobacco use (P=0.034) and parenteral drug consumption (P=0.001). No differences were found in administered therapies (P=301) neither in clinical response to chemoradiotherapy (83 vs. 100%). Moreover, similar 5-year OS (60 vs. 64%; P=0.756) and DFS (65 vs. 68%; P=0.338) were observed.ConclusionThe present study shows no significant differences in long-term oncological results among immunocompetent and immunocompromised patients diagnosed with anal SCC, with a similar oncologic treatment. This evidence might be explained due to the close monitoring and adequate therapeutic control of HIV positive patients. 相似文献
96.
97.
98.
99.
《Journal of vascular and interventional radiology : JVIR》2022,33(6):660-667
PurposeTo investigate the safety and efficacy of an aqueous polyethylene glycol-based liquid embolic agent, Embrace Hydrogel Embolic System (HES), in the treatment of benign and malignant hypervascular tumors.Materials and MethodsA prospective, single-arm, multicenter study included 8 patients, 5 males and 3 females, with a median age of 58.5 years (30–85 years), who underwent embolization in 8 tumors between October 2019 and May 2020. Technical success was defined as successful delivery of HES to the index vessel, with disappearance of >90% of the targeted vascular enhancement or, for portal vein embolization, occlusion of the portal branches to the liver segments for future resection. The volume of HES administered, ease of use (5 point Likert scale), administration time, and adverse events (AEs) were recorded. Evaluation was performed at 7, 30, and 90 days via clinical assessment and blood testing, and follow-up imaging was performed at 30 days.ResultsEight patients were enrolled, and 10 embolizations were performed in 8 lesions. Tumors included hepatocellular carcinoma (n = 4), renal angiomyolipoma (n = 3), and intrahepatic cholangiocarcinoma (n = 1). Technical success was 100%, and the average ease of use was 3.3 ± 1.0 SD. The HES delivery time was 1–28 minutes (median, 16.5 minutes), and the HES volume injected was 0.4–4.0 mL (median, 1.3 mL). All patients reached 30-day follow-up with imaging, and 6 patients reached 90-day follow-up. There were 3 serious AEs in 2 patients that were unrelated to the embolic agent.ConclusionHES resulted in a 100% embolization technical success rate. The product ease of use was acceptable, and no target vessel recanalization was noted on follow-up imaging at 30 days. 相似文献
100.